IRIS
AURIEMMA, RENATA SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.738
NA - Nord America 2.937
EU - Europa 2.801
SA - Sud America 568
AF - Africa 97
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 10.150
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.799
SG - Singapore 2.007
RU - Federazione Russa 1.499
CN - Cina 865
BR - Brasile 445
HK - Hong Kong 352
IT - Italia 326
VN - Vietnam 268
DE - Germania 212
SE - Svezia 155
FI - Finlandia 136
NL - Olanda 109
CA - Canada 77
IE - Irlanda 73
GB - Regno Unito 72
UA - Ucraina 62
AR - Argentina 59
FR - Francia 49
IN - India 49
BD - Bangladesh 36
MX - Messico 36
KR - Corea 29
CI - Costa d'Avorio 25
ZA - Sudafrica 25
EC - Ecuador 23
PL - Polonia 22
TR - Turchia 19
ES - Italia 18
IQ - Iraq 16
AT - Austria 14
IR - Iran 13
ID - Indonesia 12
CO - Colombia 11
JP - Giappone 10
KE - Kenya 10
LT - Lituania 10
BE - Belgio 8
VE - Venezuela 8
CZ - Repubblica Ceca 7
EG - Egitto 7
IL - Israele 7
MA - Marocco 7
PK - Pakistan 7
PY - Paraguay 7
UZ - Uzbekistan 7
AE - Emirati Arabi Uniti 5
CL - Cile 5
UY - Uruguay 5
CH - Svizzera 4
DO - Repubblica Dominicana 4
JM - Giamaica 4
LB - Libano 4
OM - Oman 4
PT - Portogallo 4
SA - Arabia Saudita 4
TN - Tunisia 4
AL - Albania 3
DZ - Algeria 3
JO - Giordania 3
PA - Panama 3
PE - Perù 3
AM - Armenia 2
AO - Angola 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
EE - Estonia 2
GA - Gabon 2
GM - Gambi 2
GT - Guatemala 2
HN - Honduras 2
LC - Santa Lucia 2
LK - Sri Lanka 2
NZ - Nuova Zelanda 2
PF - Polinesia Francese 2
RO - Romania 2
RW - Ruanda 2
SN - Senegal 2
TH - Thailandia 2
TL - Timor Orientale 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AU - Australia 1
BB - Barbados 1
BG - Bulgaria 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CV - Capo Verde 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
GH - Ghana 1
GP - Guadalupe 1
GR - Grecia 1
HT - Haiti 1
Totale 10.130
Salva come PNG Salva come JPEG
Città #
Singapore 910
Moscow 381
Chandler 369
Hong Kong 352
Beijing 261
Ashburn 239
Hefei 165
Santa Clara 138
San Jose 132
Naples 110
Munich 103
Millbury 98
Ho Chi Minh City 96
Amsterdam 92
Los Angeles 83
Princeton 72
Jacksonville 70
The Dalles 65
Nanjing 59
Hanoi 58
Boston 52
Wilmington 51
Redondo Beach 43
São Paulo 42
Buffalo 40
Helsinki 37
New York 37
Napoli 36
Ottawa 36
Seattle 36
Woodbridge 32
Turku 31
Dallas 29
Des Moines 27
Seoul 27
Houston 23
Falls Church 21
Falkenstein 20
Hebei 19
Warsaw 19
Mexico City 18
Montreal 18
Orem 17
Chicago 16
Nanchang 16
Phoenix 16
San Francisco 16
Frankfurt am Main 15
Rome 15
Shenyang 15
Stockholm 15
Lawrence 14
Toronto 14
Denver 13
Nuremberg 13
Rio de Janeiro 13
Ann Arbor 12
Dublin 12
Haiphong 12
Johannesburg 12
Quito 12
Ardabil 11
Changsha 11
Jiaxing 11
Ankara 10
Boydton 10
Curitiba 10
Da Nang 10
Nairobi 10
Tianjin 10
Atlanta 9
Brooklyn 9
Dhaka 9
Kronberg 9
Manchester 9
Poplar 9
Porto Alegre 9
San Mateo 9
Shanghai 9
Tokyo 9
Augusta 8
Boardman 8
Bologna 8
London 8
Salvador 8
Charlotte 7
Kochi 7
Mumbai 7
Norwalk 7
Afragola 6
Baghdad 6
Belo Horizonte 6
Brasília 6
Brussels 6
Buenos Aires 6
Chennai 6
Guangzhou 6
Hastings 6
Hải Dương 6
Joinville 6
Totale 5.132
Salva come PNG Salva come JPEG
Nome #
Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age 152
The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study 132
Circulating myomiRNAs as biomarkers in patients with Cushing's syndrome 131
The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. 130
Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly 127
Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial 124
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group 123
New perspectives in the medical treatment of acromegaly 122
Bisphenol A: An emerging threat to female fertility 122
Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. 121
Hypertension in acromegaly and in the normal population: prevalence and determinants 120
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma 120
Adverse events associated with somatostatin analogs in acromegaly. 119
Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors. 118
Erratum to: The treatment with pasireotide in Cushing’s disease: effects of long–term treatment on tumor mass in the experience of a single center (Endocrine, (2015), 50, (725-740) DOI 10.1007/s12020-015-0557-2) 118
Impact of Somatostatin Analogs vs. Surgery on glucose metabolism in acromegaly: Results of a 5 years observational, open, prospective study 117
The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients 116
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance 116
Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit 116
Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly 115
The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center. 114
Fertility in Acromegaly: a single center experience on female patients during active disease and after disease remission 111
Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: A retrospective, comparative, head-to-head study 111
The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission. 110
The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology 109
Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma 109
Acromegaly and the cardiovascular system 107
An evaluation of patients with hyperprolactinemia: have dynamic tests had their day? 106
Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. 106
Effect of Cabergoline on Metabolism in Prolactinomas. 105
Approach to the Patient with Prolactinoma 104
Mediterranean Diet: What Are the Consequences for Menopause? 104
Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. 104
Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients with Prolactinomas 104
The Vaginal Microbiome: A Long Urogenital Colonization Throughout Woman Life 104
Cardiovascular disease in Cushing's syndrome: heart versus vasculature. 103
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting 103
Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. 100
Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center 99
A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients 99
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients 99
Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects. 99
Effects of initial therapy for five years with somatostatin analogs foracromegaly on growth hormone and insulin-like growth factor-I levels, tumorshrinkage, and cardiovascular disease: a prospective study. 99
Investigational drugs for the treatment of acromegaly: new agents to transform therapy 98
Global psychological assessment with the evaluation of life and sleep quality and sexual and cognitive function in a large number of patients with acromegaly: a cross-sectional study 97
Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study 97
Early Left Ventricular Diastolic Dysfunction in Females with Chronic Hyperprolactinemia: A Doppler Echocardiographic Study 96
Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study 95
Somatostatin analogs in the clinical management of pituitary neoplasms 95
Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. 94
Effect of the acute administration of the Dopamine Agonist Cabergoline on glucose tolerance and Insuline Sensitivity in patient with obesity. 94
Glycometabolic control in Acromegalic patients with Diabetes: a study of the effects of different treatments for GH excess and for hyperglycaemia. 92
Severe systemic complications of acromegaly 91
Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment 91
The environment and male reproductive system: the potential role and underlying mechanisms of cadmium in testis cancer 90
Cardiometabolic effects of hypoprolactinemia 90
The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs 90
Increased risk of osteoporosis in postmenopausal women with type 2 diabetes mellitus: a three-year longitudinal study with phalangeal QUS measurements 90
Metabolic effects of prolactin 90
Prolactin effects on the pathogenesis of diabetes mellitus 89
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms 88
Metabolic syndrome in the era of COVID-19 outbreak: impact of lockdown on cardiometabolic health 88
Cabergoline counteracts adipose and skeletal muscle lipid accumulation: A novel therapeutic approach to obesity? 87
Erratum to: Pituitary tumors and pregnancy: The interplay between a pathologic condition and a physiologic status (Journal of Endocrinological Investigation (2014) 37, (99-112) DOI: 10.1007/s40618-013-0019-8) 87
Risk Assessment of Diabetes Mellitus during and after Pregnancy in Women with Prolactinomas 86
Medical consequences of acromegaly: what are the effects of biochemical control? 86
Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). 86
Hyperprolactinemia after menopause: Diagnosis and management 86
Efficacy and tolerability of treatment with pegvisomant in acromegaly: An overview of literature 85
Treatment with GH receptor antagonist in acromegaly:effect on cardiac arrhythmias. 83
The safety of treatments for prolactinomas 83
Prevalence of the Metabolic Syndrome in moderately-severely obese subjects with and without Growth Hormone Deficiency. 83
Acromegaly and changes in growth parameters: A focus on cardiovascular,metabolic, respiratory abnormalities, malignancies, and bone alterations 83
The role of somatostatin receptors in the medical treatment of acromegaly 82
Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly 81
TREATMENT WITH GROWTH HORMONE RECEPTOR ANTAGONIST IN ACROMEGALY: EFFECT ON CARDIAC ARRHYTHMIAS. 80
Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs 79
Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy 79
Pituitary carcinomas. 79
Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance 78
Glucose abnormalities associated to prolactin secreting pituitary adenomas 76
Diabetes mellitus, vaginal microbiome and sexual function: Outcomes in postmenopausal women 75
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. 75
Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience 73
Microalbuminuria in insulin sensitivity in patients with growth hormone-secreting pituitary tumor 73
Effects of the metabolic syndrome (METS) on gonadal function and sperm parameters in acromegalic patients: a retrospective analisys 73
Evaluation of the retinal nerve fibre layer and ganglion cell complex thickness in pituitary macroadenomas without chiasmal compression. 72
Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities 71
Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas 71
Clinical and genetic characterization of pituitary gigantism: An international collaborative study in 208 patients 70
PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an in vitro model of hepatocellular carcinoma 69
Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-monthstudy. 67
Different effect of acute administration of the dopamine agonist cabergoline on glucose tolerance and insulin sensitivity in obese pateints in relation to GH status. 67
Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. 65
Cabergoline use for pituitary tumors and valvular disorders. 65
Dopamine Agonists: From the 1970s to Today 65
Probiotics and Prebiotics: Any Role in Menopause-Related Diseases? 64
Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. 64
Clinical Case 1 62
Cushing, acromegaly, GH deficiency and tendons 59
Totale 9.492
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.255
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.255
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021120 0 0 0 0 0 0 13 3 28 11 60 5
2021/2022579 10 0 0 3 16 81 12 19 85 35 115 203
2022/2023819 97 89 21 66 97 90 4 69 144 98 34 10
2023/2024512 22 87 60 55 26 41 13 61 9 10 76 52
2024/20253.297 164 162 43 30 79 175 409 218 178 260 1.271 308
2025/20264.262 721 544 735 591 1.213 285 173 0 0 0 0 0
Totale 10.331